With the rising demand for weight-loss medications, compounding pharmacies have been making headlines lately. On October 30, the FDA announced that all doses of Novo Nordisk’s Ozempic and Wegovy ...
Since 2022, four GLP-1 drugs, including those indicated for weight loss, have been on FDA’s drug shortage list due to extraordinarily high patient demand. The shortage has, in turn, resulted in ...
Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight loss drugs Mounjaro and Zepbound, in a matter of days. That’s because a ...